Association between amantadine and the onset of dementia in Parkinson's disease
Identifieur interne : 003584 ( Main/Exploration ); précédent : 003583; suivant : 003585Association between amantadine and the onset of dementia in Parkinson's disease
Auteurs : Rivka Inzelberg [Israël] ; Ubaldo Bonuccelli [Italie] ; Edna Schechtman [Israël] ; Ala Miniowich [Israël] ; Rosa Strugatsky [Israël] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Carlo Rossi [Italie] ; Colin Klein [Israël] ; J. Martin Rabey [Israël]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-09.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Amantadine, Amantadine (therapeutic use), Antiparkinson Agents (therapeutic use), Comorbidity, Dementia, Dementia (diagnosis), Dementia (epidemiology), Dementia (prevention & control), Female, Humans, Male, Mental Status Schedule, Middle Aged, Nervous system diseases, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Parkinson's disease, Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors), Selegiline, Statistics as Topic, Survival Analysis, Treatment, amantadine, dementia, selegiline, therapy.
- MESH :
- chemical , antagonists & inhibitors : Receptors, N-Methyl-D-Aspartate.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents.
- diagnosis : Dementia, Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Dementia, Parkinson Disease.
- prevention & control : Dementia.
- Aged, Comorbidity, Female, Humans, Male, Mental Status Schedule, Middle Aged, Statistics as Topic, Survival Analysis.
Abstract
The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group). PD dementia shares neuroanatomical and biochemical similarities with Alzheimer's disease (AD). Memantine, an N‐methyl‐D‐aspartate (NMDA) receptor antagonist has been shown to be beneficial in AD. Memantine is a dimethyl derivative of amantadine, which also possesses NMDA receptor blocking properties. We hypothesized that amantadine could have a beneficial effect on the occurrence of PD dementia. PD patients attending the Movement Disorders Clinics in Hillel Yaffe, Asaf Harofe Medical Centers (Israel) and Pisa (Italy) were included. Taking the onset of dementia as the endpoint, survival curves for AM and NoAM patients were estimated by the Kaplan–Meier method. The study population consisted of 593 patients (age, 69.5 ± 9.9 years; PD duration, 9.2 ± 6.0 years; 263 patients (44%) amantadine treated). The endpoint of dementia was reached by 116 patients (20%). PD duration until dementia was significantly longer for AM patients (9.1 ± 5.7 years) than for NoAM patients (5.9 ± 4.6 years, P = 0.006). The duration of amantadine exposure positively correlated with PD duration until dementia (P = 0.0001). Survival analysis, taking dementia onset as endpoint, showed slower mental decline in AM patients (Log rank P = 0.0049, Wilcoxon P = 0.0024). Mini‐Mental State Examination scores were significantly higher for AM patients than for the NoAM group (P = 0.01). Age of PD onset also significantly influenced the duration of PD until dementia. Amantadine use may delay the onset of dementia in PD patients and may attenuate its severity. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20968
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001352
- to stream Istex, to step Curation: 001352
- to stream Istex, to step Checkpoint: 002045
- to stream PubMed, to step Corpus: 002C30
- to stream PubMed, to step Curation: 002C30
- to stream PubMed, to step Checkpoint: 002E73
- to stream Ncbi, to step Merge: 001704
- to stream Ncbi, to step Curation: 001704
- to stream Ncbi, to step Checkpoint: 001704
- to stream Main, to step Merge: 004899
- to stream PascalFrancis, to step Corpus: 001A06
- to stream PascalFrancis, to step Curation: 001315
- to stream PascalFrancis, to step Checkpoint: 001C31
- to stream Main, to step Merge: 004D26
- to stream Main, to step Curation: 003584
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association between amantadine and the onset of dementia in Parkinson's disease</title><author><name sortKey="Inzelberg, Rivka" sort="Inzelberg, Rivka" uniqKey="Inzelberg R" first="Rivka" last="Inzelberg">Rivka Inzelberg</name></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name></author><author><name sortKey="Schechtman, Edna" sort="Schechtman, Edna" uniqKey="Schechtman E" first="Edna" last="Schechtman">Edna Schechtman</name></author><author><name sortKey="Miniowich, Ala" sort="Miniowich, Ala" uniqKey="Miniowich A" first="Ala" last="Miniowich">Ala Miniowich</name></author><author><name sortKey="Strugatsky, Rosa" sort="Strugatsky, Rosa" uniqKey="Strugatsky R" first="Rosa" last="Strugatsky">Rosa Strugatsky</name></author><author><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name></author><author><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name></author><author><name sortKey="Rossi, Carlo" sort="Rossi, Carlo" uniqKey="Rossi C" first="Carlo" last="Rossi">Carlo Rossi</name></author><author><name sortKey="Klein, Colin" sort="Klein, Colin" uniqKey="Klein C" first="Colin" last="Klein">Colin Klein</name></author><author><name sortKey="Rabey, J Martin" sort="Rabey, J Martin" uniqKey="Rabey J" first="J. Martin" last="Rabey">J. Martin Rabey</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20968</idno><idno type="url">https://api.istex.fr/document/AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001352</idno><idno type="wicri:Area/Istex/Curation">001352</idno><idno type="wicri:Area/Istex/Checkpoint">002045</idno><idno type="wicri:doubleKey">0885-3185:2006:Inzelberg R:association:between:amantadine</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16705684</idno><idno type="wicri:Area/PubMed/Corpus">002C30</idno><idno type="wicri:Area/PubMed/Curation">002C30</idno><idno type="wicri:Area/PubMed/Checkpoint">002E73</idno><idno type="wicri:Area/Ncbi/Merge">001704</idno><idno type="wicri:Area/Ncbi/Curation">001704</idno><idno type="wicri:Area/Ncbi/Checkpoint">001704</idno><idno type="wicri:doubleKey">0885-3185:2006:Inzelberg R:association:between:amantadine</idno><idno type="wicri:Area/Main/Merge">004899</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0518090</idno><idno type="wicri:Area/PascalFrancis/Corpus">001A06</idno><idno type="wicri:Area/PascalFrancis/Curation">001315</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001C31</idno><idno type="wicri:doubleKey">0885-3185:2006:Inzelberg R:association:between:amantadine</idno><idno type="wicri:Area/Main/Merge">004D26</idno><idno type="wicri:Area/Main/Curation">003584</idno><idno type="wicri:Area/Main/Exploration">003584</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Association between amantadine and the onset of dementia in Parkinson's disease</title><author><name sortKey="Inzelberg, Rivka" sort="Inzelberg, Rivka" uniqKey="Inzelberg R" first="Rivka" last="Inzelberg">Rivka Inzelberg</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Hillel Yaffe Medical Center, Hadera</wicri:regionArea><wicri:noRegion>Hadera</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea><wicri:noRegion>University of Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Schechtman, Edna" sort="Schechtman, Edna" uniqKey="Schechtman E" first="Edna" last="Schechtman">Edna Schechtman</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Industrial Engineering and Management, Ben Gurion University, Beer Sheva</wicri:regionArea><wicri:noRegion>Beer Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Miniowich, Ala" sort="Miniowich, Ala" uniqKey="Miniowich A" first="Ala" last="Miniowich">Ala Miniowich</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea><wicri:noRegion>Ramat Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Strugatsky, Rosa" sort="Strugatsky, Rosa" uniqKey="Strugatsky R" first="Rosa" last="Strugatsky">Rosa Strugatsky</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Hillel Yaffe Medical Center, Hadera</wicri:regionArea><wicri:noRegion>Hadera</wicri:noRegion></affiliation></author><author><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea><wicri:noRegion>University of Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea><wicri:noRegion>University of Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Rossi, Carlo" sort="Rossi, Carlo" uniqKey="Rossi C" first="Carlo" last="Rossi">Carlo Rossi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurosciences, University of Pisa</wicri:regionArea><wicri:noRegion>University of Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Klein, Colin" sort="Klein, Colin" uniqKey="Klein C" first="Colin" last="Klein">Colin Klein</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea><wicri:noRegion>Ramat Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Rabey, J Martin" sort="Rabey, J Martin" uniqKey="Rabey J" first="J. Martin" last="Rabey">J. Martin Rabey</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Asaf Harofe Medical Center, Tzrifin and Sackler Faculty of Medicine, Tel‐Aviv University, Ramat Aviv</wicri:regionArea><wicri:noRegion>Ramat Aviv</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-09">2006-09</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1375">1375</biblScope><biblScope unit="page" to="1379">1379</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036</idno><idno type="DOI">10.1002/mds.20968</idno><idno type="ArticleID">MDS20968</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Amantadine</term><term>Amantadine (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Comorbidity</term><term>Dementia</term><term>Dementia (diagnosis)</term><term>Dementia (epidemiology)</term><term>Dementia (prevention & control)</term><term>Female</term><term>Humans</term><term>Male</term><term>Mental Status Schedule</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)</term><term>Selegiline</term><term>Statistics as Topic</term><term>Survival Analysis</term><term>Treatment</term><term>amantadine</term><term>dementia</term><term>selegiline</term><term>therapy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dementia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Comorbidity</term><term>Female</term><term>Humans</term><term>Male</term><term>Mental Status Schedule</term><term>Middle Aged</term><term>Statistics as Topic</term><term>Survival Analysis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amantadine</term><term>Démence</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Sélégiline</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group). PD dementia shares neuroanatomical and biochemical similarities with Alzheimer's disease (AD). Memantine, an N‐methyl‐D‐aspartate (NMDA) receptor antagonist has been shown to be beneficial in AD. Memantine is a dimethyl derivative of amantadine, which also possesses NMDA receptor blocking properties. We hypothesized that amantadine could have a beneficial effect on the occurrence of PD dementia. PD patients attending the Movement Disorders Clinics in Hillel Yaffe, Asaf Harofe Medical Centers (Israel) and Pisa (Italy) were included. Taking the onset of dementia as the endpoint, survival curves for AM and NoAM patients were estimated by the Kaplan–Meier method. The study population consisted of 593 patients (age, 69.5 ± 9.9 years; PD duration, 9.2 ± 6.0 years; 263 patients (44%) amantadine treated). The endpoint of dementia was reached by 116 patients (20%). PD duration until dementia was significantly longer for AM patients (9.1 ± 5.7 years) than for NoAM patients (5.9 ± 4.6 years, P = 0.006). The duration of amantadine exposure positively correlated with PD duration until dementia (P = 0.0001). Survival analysis, taking dementia onset as endpoint, showed slower mental decline in AM patients (Log rank P = 0.0049, Wilcoxon P = 0.0024). Mini‐Mental State Examination scores were significantly higher for AM patients than for the NoAM group (P = 0.01). Age of PD onset also significantly influenced the duration of PD until dementia. Amantadine use may delay the onset of dementia in PD patients and may attenuate its severity. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Israël</li><li>Italie</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Inzelberg, Rivka" sort="Inzelberg, Rivka" uniqKey="Inzelberg R" first="Rivka" last="Inzelberg">Rivka Inzelberg</name></noRegion><name sortKey="Inzelberg, Rivka" sort="Inzelberg, Rivka" uniqKey="Inzelberg R" first="Rivka" last="Inzelberg">Rivka Inzelberg</name><name sortKey="Klein, Colin" sort="Klein, Colin" uniqKey="Klein C" first="Colin" last="Klein">Colin Klein</name><name sortKey="Miniowich, Ala" sort="Miniowich, Ala" uniqKey="Miniowich A" first="Ala" last="Miniowich">Ala Miniowich</name><name sortKey="Rabey, J Martin" sort="Rabey, J Martin" uniqKey="Rabey J" first="J. Martin" last="Rabey">J. Martin Rabey</name><name sortKey="Schechtman, Edna" sort="Schechtman, Edna" uniqKey="Schechtman E" first="Edna" last="Schechtman">Edna Schechtman</name><name sortKey="Strugatsky, Rosa" sort="Strugatsky, Rosa" uniqKey="Strugatsky R" first="Rosa" last="Strugatsky">Rosa Strugatsky</name></country><country name="Italie"><noRegion><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name></noRegion><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name><name sortKey="Rossi, Carlo" sort="Rossi, Carlo" uniqKey="Rossi C" first="Carlo" last="Rossi">Carlo Rossi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003584 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003584 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AEBB6144CDA4BCBA8F00BF9EDBF063AD31C40036
|texte= Association between amantadine and the onset of dementia in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |